VitaDAO becomes the FIRST DAO to kickstart a BIOTECH company, Matrix Bio. MatrixBio explores hyaluronic acid-based compounds, aiming to pioneer in cancer and aging treatments, utilizing insights from cancer-resistant naked mole rats This significant milestone comes from a community-wide vote and approval in favor of a collaboration with Vera Gorbunova, Ph.D., Co-Chair of the University of Rochester’s Aging Research Center. Congrats to the VitaDAO team that's involved with Matrix Bio and made it possible: Todd White Anthony Schwartz, PhD Eleanor Davies Read the entire article
About us
VitaDAO is a decentralized, community-owned collective dedicated to funding and advancing early stage longevity science research. Our mission is to support researchers who are working to pre-empt the onset of age-related diseases, and to bring new therapeutics to market that allow people to live longer, healthier lives.
- Website
-
https://www.vitadao.com/
External link for VitaDAO
- Industry
- Research Services
- Company size
- 51-200 employees
- Type
- Public Company
- Founded
- 2021
Employees at VitaDAO
Updates
-
At the VitaDAO DeSci Summit, Anthony Schwartz of VitaRNA showcased how funding science on-chain is revolutionizing biotech. Exciting progress in drug candidates, with clinical trials on the horizon. https://lnkd.in/d9mRUrft
Launching a Biotech Company via Crypto | Anthony Schwartz (VitaRNA)
https://www.youtube.com/
-
VitaDAO reposted this
🧬 Accelerating progress in longevity biotech to extend healthy lifespan via new cities 🏙️ @Vitalia.city #Zuzalu 💛 Founding steward @VitaDAO 🎬Films @JellyfishDAO
Did you know there's an International Longevity Day tomorrow, Oct 1st? Join a meetup in your city: - Germany (Berlin) - US (San Francisco) - Spain - Latvia - Romania - Bulgaria - Slovenia - Sweden - Israel - Nigeria etc I'll be at the one in Berlin https://lnkd.in/ehb24WnD
Longevity Day and Month of October 2024
https://longevityalliance.org
-
If you’ve never experienced a longevity pop-up city, definitely check out https://zelar.city 📅 Coming up on Oct 5 - Nov 17 📍 Berlin
Let’s cut to the chase: aging is the enemy. People are suffering and dying from age-related diseases every single day, and we’re stuck in this slow-motion bureaucratic nightmare. The clock is ticking, and we’re running out of time. But here’s the kicker: aging can be solved. We’ve got the science, and the momentum is real. So why aren’t we moving faster? Here’s why: we’re trapped in a system that’s holding us back. The FDA. Government regulations. Centralized health systems. They are slow. They are bureaucratic. And they are failing us. The longer we rely on this broken system, the more lives we lose. But what happens when a group of people (highly aligned and committed to curing aging) decide they’re done playing by these rules? What happens when they create their own space, free from the bottlenecks, and build the future on their terms? That’s the real answer. It’s not simple, but it’s the only path forward. We need to create something entirely new. Think of it as a network society, a place where people who are not just dreaming about longer life, but actively working to make it happen, come together. No more waiting for approvals. No more waiting for someone else to act. We take control. What does that look like? Forget about centralized authorities slowing us down. We’re talking about a new state, a new society where the best minds work together. Scientists, innovators, entrepreneurs. They’re not just sitting in labs, they’re collaborating in real-time. They’re building solutions that can’t be born in the old system. Think about it. The Manhattan Project wasn’t bogged down by bureaucracy. It brought together the brightest minds to tackle a seemingly impossible problem, without roadblocks. What if we used that same approach to solve aging? What if we brought the same level of focus and resources to this? The breakthroughs would happen faster than any government agency could ever allow. And guess what? This isn’t some far-off fantasy. It’s starting now. We’re seeing the birth of pop-up cities like Zuzalu, Vitalia, and Zelar.city, where people come together to innovate and push the boundaries of longevity research. We’re pooling our resources, our intelligence, and our drive to make this future a reality. And the future won’t be decided by government approvals. It will be built by us, by people who know that aging is the real problem we must solve. Here’s the deal: if you’re serious about changing the future, you can’t just sit back and wait. You have to get involved. We’re not just talking about extending healthspan. This is about creating more time. More life. Ending suffering and death, and building a world where aging no longer defines our limits. The world we’re building is going to look different. It has to. And if you’re not part of it, you’re going to be left behind. Waiting around is so last century. At Zelar City, we’re building a future where aging is optional. Visit us: https://zelar.city
-
Innovative Alzheimer's research explores infection-dementia link, aiming for early diagnosis tool & potential vaccine. VitaDAO contributed $50K to Project AB4AD on @Molecule AG's Catalyst, but community support is crucial. Join the fight against Alzheimer's https://lnkd.in/dw38qqin
-
VitaDAO reposted this
It must be 2024! - We are using crypto to finance AAV gene therapy projects??? Nice work Anthony Schwartz Michael Torres VitaDAO
Building a real world biotech company with crypto! We’re doing it and actually generating exciting data! It was great to have our CEO, Anthony Schwartz, share insights at Token2049. Learn more about the science and token at vitarna.xyz.
-
VitaDAO reposted this
Congrats to Oisin Biotechnologies, a VitaDAO-backed #longevity #biotech company, who has just announced the publication of promising preclinical data for their gene therapy program!
Big news! We’re thrilled to announce the publication of Oisín’s preclinical data in Cell Press showcasing the potential of our follistatin gene therapy program to combat muscle loss and increase strength. The findings not only validate our decision to be early adopters of the FAST-PLV™ platform developed by Entos Pharmaceuticals, but also provide proof-of-principle as we advance our muscle building program. This milestone is an important step forward in our mission to develop safer and more effective therapies for an aging population. Matthew Scholz, Douglas Brown, John Lewis, Arun Raturi, Hank Garcia, Ping Wee, PraKash Bhandari, Roy Duncan, Hector Vega, Maryam Hejazi, Deborah L. Sosnowski, Jailal Ablack, Eileen Clancy, Desmond Pink, Jitendra Kumar, Paola Solís Ares, Lilya Grin, Suellen Lamb, Rodrigo Margain Quevedo, Bijal Rawal, Fahed Elian, MSc, Ph.D, Natasha Rana, Luis Carlos Morales MD, MSc, PhD, Natasha Govindasamy, Brendan Todd, Ph.D., Angela Delmage, Somnath Gupta, Nichole McMullen, Duncan MacKenzie, Perrin Beatty, Manoj Parmar, Jenn Gyoba, Chandra McAllister, Gary Hudson, Stephen Hilbert, Eric Garcia, Alexandre R. Gingras Take a look here: https://lnkd.in/gTmiXvra
Safe and effective in vivo delivery of DNA and RNA using proteolipid vehicles
sciencedirect.com
-
HDAX Therapeutics, a project funded by the VitaDAO community, closes oversubscribed $3.2M seed round 💛 Their novel HDAC6-targeting approach shows promise for neurological & cardiometabolic diseases. A big step towards transformative therapies! 🌱 https://lnkd.in/eMuEr-bw
HDAX Therapeutics Announces First Closing of Oversubscribed US $3.2 (CA $4.3) Million Seed Financing
businesswire.com
-
Nice writeup by @LifespanIO on longevity news for August 2024! BeakerDAO, VitaDAO & Cerebrum DAO raise 76 ETH (~$200K) for innovative neurodegenerative disease research. Project targets root causes by improving protein production accuracy. https://lnkd.in/d--Nsfz2
Longevity Market Recap – August 2024
https://www.lifespan.io
-
We've funded Fission Pharma together with Cerebrum DAO They’re working on a new way to treat age-related diseases by breaking the link between chronic inflammation and damaged mitochondria, aiming to help us live longer. Chronic inflammation can mess up our mitochondria, the powerhouses of our cells, leading to various diseases. Fission Pharma targets a specific protein interaction that only happens during stress, making it a perfect target for treatment P110, a peptide originating from Stanford University, protects mitochondria by inhibiting harmful interactions. It’s been tested for 13 years, showing great results. But its peptide form limits its use as a drug. Fission Pharma is now creating small molecule versions of P110, which work just as well in models of ALS and sepsis. These molecules are easier to take as medication and don’t suppress the immune system. The goal is to make the first effective, orally available, brain-penetrant treatments for chronic inflammation and mitochondrial dysfunction, crucial for fighting aging. Starting with ALS, Fission Pharma plans to expand to diseases like Alzheimer's and heart disease, tackling major issues that limit our lifespan. Learn more about the project https://lnkd.in/d8wgFQjN
VitaDAO - Fission Pharma
vitadao.com